Sodium-glucose cotransporter 2 (SGLT2) inhibitors have fundamentally reshaped the pharmacological management of chronic heart failure (HF). However, the role of these inhibitors during the vulnerable phase of acute decompensated heart failure (ADHF) has historically been limited by concerns regarding hemodynamic stabil...
A. Mauriello, Adriana Correra, A. Maratea et al.· Reviews in cardiovascular me...· 0 citations
The therapeutic landscape of cardiorenal syndrome (CRS) has evolved significantly, transitioning from historical cornerstones like angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to modern neurohormonal modulation with angiotensin receptor–neprilysin inhibitors (ARNIs). This seco...
A. Mauriello, V. Cetoretta, Carmen Del Giudice et al.· Biomedicines· 0 citations
Despite a predominantly low HFA-ICOS risk profile, nearly one-fifth of patients in this contemporary cohort developed significant cardiovascular complications, including symptomatic heart failure and new-onset arrhythmias, so a proactive and multidisciplinary monitoring strategy is mandatory for all patients receiving...
F. Guerra, E. Rrapaj, A. Frangione et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.